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Abstract: Alzheimer’s disease (AD) is a progressive neurodegenerative disease 
characterized by microscopic lesions consisting of beta-amyloid plaques and 
neurofibrillary tangles (NFTs). The majority of cases are defined as sporadic and are likely 
caused by a combination of both genetic and environmental factors. Of the genetic risk 
factors identified, the 34 kDa protein, apolipoprotein (apo) E4, is of significant importance 
as APOE4 carriers account for 65%–80% of all AD cases. Although apoE4 plays a normal 
role in lipoprotein transport, how it contributes to AD pathogenesis is currently unknown. 
One potential mechanism by which apoE4 contributes to disease risk is its propensity to 
undergo proteolytic cleavage generating N- and C-terminal fragments. The purpose of this 
review will be to examine the mechanisms by which apoE4 contributes to AD pathogenesis 
focusing on the potential loss or gain of function that may occur following cleavage of the 
full-length protein. In this context, a discussion of whether targeting apoE4 therapeutically 
is a rationale approach to treating this disease will be assessed. 
Keywords: apolipoprotein E; apoE4; Alzheimer’s disease; beta amyloid; neurofibrillary 
tangles; proteolysis; cleavage; neurodegeneration 
 
1. Introduction to Alzheimer’s Disease 
According to the most recent facts and figures, Alzheimer’s disease (AD) affects approximately  
5.2 million Americans, with the vast majority over the age of 65 [1]. Currently, AD is the sixth-leading 
cause of death in the United States and the fifth-leading cause of death for individuals age 65 and  
older [2]. AD is progressive neurodegenerative disorder characterized by an array of symptoms 
affecting memory and cognition. Some common symptoms of AD include memory loss that disrupts 
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daily life, challenges in planning or solving problems, confusion with time or place, and changes in 
mood and personality [2]. Collectively these symptoms represent the term dementia, and AD is by far 
the most common cause of dementia in the United States accounting for 60 to 80 percent of cases [2]. 
In an effort to recognize the importance of early prevention and detection, new guidelines have been 
established for AD, the first since 1984 [3]. The three new stages of AD include: (1) preclinical AD 
that underscores the fact that the AD process begins before there are any overt symptoms of dementia; 
(2) mild cognitive impairment that includes patients with changes in memory and thinking ability but 
are not individuals classified as having AD. However, many of these patients will develop Alzheimer’s 
dementia; and (3) dementia, including mental impairments not as severe as those previously required 
for an Alzheimer’s diagnosis. 
1.1. Pathology of Alzheimer’s Disease 
Pathologically, AD is characterized by two microscopic lesions that include senile plaques and 
neurofibrillary tangles (NFTs). Both lesions must be present in order to have a post-mortem diagnosis 
of AD, and one never occurs without the other. Senile plaques are extracellular deposits of  
beta-amyloid, a 40–42 amino acid peptide that is derived following the processing of the amyloid 
precursor protein (APP) by beta and gamma secretases. Once formed, beta-amyloid has the propensity 
to self-aggregate into β-sheet structures that deposit extracellularly forming senile plaques (Figure 1). 
More recently, the beta-amyloid hypothesis has been revised to the “toxic beta-amyloid oligomer” 
hypothesis to reconcile the apparent lack of correlation between beta-amyloid in plaques and cognitive 
impairment [4]. This reformulation of the amyloid cascade hypothesis focuses on oligomeric 
aggregates of beta-amyloid as the prime toxic species causing AD in part because this form of  
beta-amyloid strongly correlates with the severity of dementia [5,6]. In addition, this oligomeric form 
of beta-amyloid is highly toxic and is the trigger for the loss of synapses and neuronal damage [7,8] 
(See Figure 2). 
Specifically, beta-amyloid dimers have been isolated from the cortex of human AD cases and were 
the most abundant beta-amyloid species identified [9]. Importantly, Jin et al. demonstrated that natural 
dimers isolated from the AD brain induced phosphorylation of tau and neuritic degeneration that can 
be prevented following passive immunization with several beta-amyloid antibodies [9]. The next step 
in this process will be to identify the potential mechanisms by which beta-amyloid dimers induce 
neuritic changes within the AD brain. It has been hypothesized that beta-amyloid acting as dimers or 
multimers interface with neuronal cell membranes to induce tau modifications and subsequent 
neurodegeneration [10]. 
The other major pathological finding in AD is the presence of NFTs [11]. NFTs are primarily 
composed of aggregated phosphorylated tau protein and are a clinical feature not just in AD, but other 
diseases that are collectively referred to as “tauopathies” [12]. Tau normally functions to help maintain 
the stability of the cytoskeleton of neurons by binding to microtubules. However, upon 
hyperphosphorylation and posttranslational cleavage, tau loses its binding affinity for microtubules, 
leading to a destabilization of the cytoskeleton and self-assembly of tau into tangles of paired helical 
filaments (PHF-1) [13]. 
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Figure 1. The amino terminal fragment of apolipoprotein (apo) E4 (apoE4) localizes to 
neurofibrillary tangles (NFTs) in the Alzheimer’s disease (AD) brain. (A) Representative 
bright field microscopy image from frontal cortex AD brain sections utilizing anti-Aβ 
antibody, clone 6E10 (blue-black) together with a custom synthesized antibody that 
specifically detects the amino terminal fragment of apoE4 (brown) revealed specific 
localization of this fragment within NFTs, in this case near an extracellular plaque labeled 
with an anti-Aβ antibody (arrow); (B) Double-label immunofluorescence using paired 
helical filaments (PHF-1) (red) as a marker for NFTs and the custom antibody to the amino 
terminal fragment of apoE4 (green) showed strong colocalization (yellow) in a subset of 
tangles in the AD brain (arrow). Scale bars are 10 µm for (A) and 20 µm for (B). 
 
According to the beta-amyloid hypothesis, the accumulation and aggregation of beta-amyloid into 
toxic soluble oligomers is the first step leading to neuronal degeneration in AD [14]. Specifically, an 
important early molecular step is the lost of synapses, which correlates highly with the initial memory 
impairment observed in AD [15,16]. Intensive research over the last two decades has examined 
potential pathways activated by beta-amyloid aggregates that lead to synaptic dysfunction, NFT 
formation, and eventual cell death. Figure 2 summarizes some of the major findings on  
beta-amyloid-induced toxicity that begin with either beta-amyloid activation of apoptotic pathways or 
promotion of oxidative stress.  
1.2. Risk Factors Associated with Alzheimer’s Disease 
By far the greatest risk factor for AD is advancing age affecting 11 percent of those age 65 and 
older and 32 percent of people age 85 and older [1]. A small percentage of cases (<1%) are caused by 
known mutations in the APP gene or genes products involved in processing APP to form beta-amyloid 
and thus far, all identified mutations have the overall effect of enhancing the production of the  
beta-amyloid peptide (for a recent review, see [17]). The majority of these cases manifest before the 
age of 60 and therefore are classified as early-onset AD. Other known mutations that lead to  
early-onset AD include those to presenilin 1 (PSEN1) and presenilin 2 (PSEN2), whose gene products 
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comprise the gamma-secretase complex [18,19]. The net effect of mutations to these two genes is 
enhanced production of beta-amyloid perhaps by shifting the cleavage site in APP [20].  
Figure 2. Proteolysis of apoE4 leads to a gain of function. The figure summarizes key 
features associated with AD including the formation of beta-amyloid by beta/gamma 
secretase and the deposition into extracellular plaques as well as formation of NFTs. A 
revision of the beta-amyloid hypothesis, as it has become known, is the role that oligomeric 
forms of beta-amyloid may play in disease progression. Thus, beta-amyloid oligomers now 
are thought to represent the cytotoxic species that can confer synapse loss, oxidative stress 
and neuronal damage. A key step in this process is mitochondrial disruption by  
beta-amyloid oligomers that may lead to the activation of apoptotic pathways in the AD 
brain. ApoE4 may promote the pathogenesis underlying AD following cleavage and 
generation of an N-terminal fragment. This fragment in turn may lead to a toxic gain of 
function of apoE4 in three ways: (1) Disruption of mitochondrial function by impairment 
of enzymes involved in the respiratory chain complex; (2) Promotion on the intracellular 
accumulation of beta-amyloid by stimulating cellular uptake; (3) induce tangle-like 
inclusions resembling neurofibrillary tangles. The cumulative end results of these 
processes may lead to enhanced pathology, neuronal deficits in memory and learning, and 
neurodegeneration. See main text for details. 
 
Despite intensive research efforts, few candidate genes have been identified as potential risk factors 
for late-onset AD, representing those cases over the age of 65. A recent genetic analysis has suggested 
a link to mutations in various genes including A2M (encoding alpha-2-macroglobulin), ABCA1 and 2 
(encoding ATP-binding cassette transporters 1 and 2, respectively), CLU (encoding clusterin), 
PICALM (encoding the phosphatidylinositol binding clathrin assembly protein) and SORL1 (encoding 
sortilin-related receptor gene) (for a review, see [21]).  
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Two other candidate genes that confer risk for late-onset AD include the TREM2 and APOE4 gene. 
Recently, two significant genetic variants of TREM2 have been identified as increasing the risk for 
late-onset AD. The TREM2 gene encodes the protein, triggering receptor expressed on myeloid cells  
2 (TREM2). TREM2 variants increase the risk for AD approximately 3-fold [22,23]. Activation of the 
TREM2 receptor protein on microglia has two important function consequences: (1) stimulation of 
phagocytosis activity and (2) decreased microglial proinflammatory responses [24]. Collectively, the 
TREM2 protein may function to help aid microglia to clear damaged or apoptotic cells, cellular debris 
and help resolve damage-induced inflammation. It has been suggested that both of these TREM2 
variants may lead to the expression of a non-functional TREM2 protein and loss of these critical 
functions in microglia. The other major risk factor for developing late-onset AD is harboring the 
apolipoprotein E4 (APOE4) allele [25]. Although harboring the APOE4 allele clearly enhances the risk 
for AD, the mechanism by which the apoE4 protein contributes to AD pathogenesis is not known. The 
focus of this review is to highlight some of the putative mechanisms by which apoE4 contributes to 
AD pathogenesis. 
2. Apolipoprotein E: Structure and Function 
Human apoE is polymorphic with three major isoforms, apoE2, apoE3, and apoE4, which differ by 
single amino acid substitutions involving cysteine-arginine replacements at positions 112 and 158 [26]. 
Harboring the APOE3 allele is believed to neither increase nor decrease one’s risk of AD, while having 
the E2 form may decrease one’s risk. In contrast, inheritance of one copy of the APOE4 allele 
increases disease risk fourfold, while two copies raises the risk tenfold [25]. It is noteworthy that  
65%–80% of all AD patients have at least one APOE4 allele [27,28]. Structurally, apoE4 is a 34 kDa 
protein composed of 299 amino acids and contains two major domains, referred to as the N-terminal 
(~20 kDa) and C-terminal (~10 kDa) domains, which are connected by a short hinge region [29] 
(Figure 2). Functionally, in the CNS, apoE is produced by a variety of cells including astrocytes, and 
transports cholesterol to neurons via apoE receptors, which are members of the low-density lipoprotein 
(LDL) receptor family [30,31]. It has been proposed that because apoE is the major cholesterol 
transporter in the brain (see below) and therefore is essential for synaptogenesis in neurons, then  
apoE-isoform-dependent differences in these processes may negatively impact synaptic plasticity or 
recovery of neurons from neurodegeneration as might occur in AD [32,33]. 
3. Proteolysis of apoE4 as a Mechanism Underlying Pathogenesis in AD 
Although apoE4 plays a normal role in lipoprotein transport, how it contributes to AD pathogenesis 
is currently unknown. An emerging clue to this puzzle are data demonstrating that apoE4 is highly 
susceptible to proteolysis compared to the other major isoforms of apoE [34]. In this regard, the hinge 
region of apoE4 has multiple protease-sensitive sites and although the exact nature of the protease 
involved in cleaving apoE4 is unknown several candidates have been reported including  
cathepsin D [35], a chymotrypsin-like protease [34], and aspartic proteases [36]. Although evidence 
suggests the hinge region of apoE4 represents a region of proteolytic susceptibility, it is clear based on 
the number of different fragments demonstrated to occur in human brain homogenates, that other 
regions within apoE4 including the N- and C-terminal domains are also susceptible to cleavage [37]. In 
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mouse models of AD, proteolytic cleavage of apoE4 has been demonstrated in neurons, not astrocytes, 
to accumulate in an age-dependent manner, and cause AD-like memory deficits [34,38,39]. These data 
support the hypothesis that intraneuronal proteolytic cleavage of apoE4 could promote the 
neuropathology and neurodegeneration in AD brains. Supporting a role of proteolytic cleavage of apoE4 
are studies demonstrating the presence of apoE4 fragments (14–20 kDa) in the AD brain [34,40–42]. 
Intriguing, is following the cleavage of apoE4 into two distinct domains, each domain appears to 
localize to specific pathological lesions in the AD brain. Thus, the C-terminal domain of apoE4 has 
been implicated in binding to beta-amyloid and is localized to plaques [36,40,42]. On the other hand, 
the N-terminal domain preferentially localizes within NFTs [34]. We recently confirmed the specific 
localization of the N-terminal domain of apoE4 to NFTs in the AD brain by synthesizing a  
site-directed antibody to a putative cleavage site within apoE4 at position D172. This antibody, which 
detects only the N-terminal fragment of apoE4 localized exclusively within NFTs of the AD brain [42] 
(Figure 1). The high susceptibility of apoE4 to proteolytic cleavage may be the driving force behind 
the enhanced risk for AD in individuals who are either heterozygous or homozygous for the APOE4 
allele. Emerging data suggests the cleavage of apoE4 may increase AD risk in two ways, either 
through a loss of function or gain of toxicity. 
3.1. Proteolysis of apoE4 Leads to Loss of Function 
Variations in the APOE gene sequence results in three common alleles, E2, E3, and E4, represented 
with frequencies of 8%, 77%, and 15%, respectively, in the population [43]. As stated above, apoE4 is 
highly susceptible to proteolysis as compared to the other isoforms and this cleavage may result in loss 
of function. An important role of apoE is its ability to transport cholesterol within the CNS. CNS apoE 
is synthesized locally in the brain by neurons [44], astrocytes [45], and microglia [46]. With respect to 
neurons, Xu et al. eloquently demonstrated in green fluorescent apoE protein reporter mice that under 
normal conditions neurons express very little apoE protein. However, in response to excitotoxic injury, 
neurons responded with a significant increase in apoE expression [47]. Importantly, the plasma pool of 
apoE does not appear to exchange with the brain pool due to the presence of the blood brain barrier 
and consequently, there is no mixing of cholesterol pools between the brain and the periphery [48]. 
Transport of cholesterol by apoE may provide neurons the necessary cholesterol required for synapse 
formation, plasticity, and repair [49]. Moreover, synaptic development and plasticity are governed by 
the availability of cholesterol and decline with aging, suggesting a pivotal role for apoE in aging [50].  
In addition to cholesterol, current evidence suggests that apoE plays an important role in 
transporting beta-amyloid in the AD brain. It has been suggested that apoE binds beta-amyloid directly 
to influence its clearance (for review, see [51]). Specifically, it has been proposed that  
astrocyte-derived apoE is critical for the degradation and clearance of deposited beta-amyloid, and that 
this process may be impaired in AD [52]. Recently, Bien-Ly et al. crossed an AD mouse model with 
mice that express C-terminal-truncated apoE4 and showed these mice had a lower affinity for  
beta-amyloid and a reduced ability to clear beta-amyloid [39]. In addition, the C-terminal-truncated 
fragment of apoE4 acted in concert with beta-amyloid to promote behavior deficits in these mice [39]. 
Further support for a critical role of apoE-mediated removal of beta-amyloid are recent studies 
demonstrating the administration of anti-cancer drug, bexarotene in an animal model of AD, enhanced 
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clearance of beta-amyloid and reversed cognitive impairments in an apoE-dependent manner [53,54]. 
However, the exact mechanism by which apoE enhances clearance of beta-amyloid plaque loads is 
unclear [55–57]. It has been proposed that apoE can bind to beta-amyloid and undergo endocytosis via 
the astrocyte low-density lipoprotein receptor-related protein (LRP) [58,59]. 
Figure 3. Proteolysis of apoE4 leads to a loss of normal function. Following cleavage of 
apoE4 by as yet an unidentified protease, could hypothetically lead to a loss of function of 
apoE4; including: (1) Impairment of cholesterol transport. In the CNS, apoE is one of the 
major lipid acceptors and functions to shuttle cholesterol to and from cells to generate 
high-density lipoprotein (HDL) particles. Loss of this function could deplete  
HDL-cholesterol that is essential for synaptogenesis and neurite outgrowth in neurons and 
thereby limit the recovery from neurodegeneration observed in AD; (2) AD is associated 
with impaired clearance of beta-amyloid from the brain, a process that is normally 
facilitated by apoE. In this regard, apoE4 is known to bind directly to oligomeric  
beta-amyloid enhancing its clearance out of the CNS and although it does this very poorly 
as compared to apoE2 and apoE3, proteolytic cleavage could further exacerbate this 
important role in individuals harboring the apoE4 allele in AD. 
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Given the preponderance of data suggesting a critical role of apoE in enhancing beta-amyloid 
clearance, cleavage of apoE4 following its expression may cause a loss of this important function 
leading to accumulation and aggregation of toxic beta-amyloid species. Indeed, a recent study has 
demonstrated a differential regulation of beta-amyloid clearance by isoforms of apoE, with apoE3 
being more efficient in this process than apoE4 [60]. Taken together, the expression apoE4, 
susceptibility of cleavage and eventual loss of function both in cholesterol transport and beta-amyloid 
clearance may explain the heightened risk for developing AD associating with expression of the 
APOE4 allele (Figure 3). 
3.2. Proteolysis of apoE4 Leads to a Toxicity Gain of Function 
Proteolytic cleavage of apoE4 may not only lead to loss of function, but current evidence suggests 
that generated fragments can produce a toxic-gain of function. For example, cleavage of apoE4 
produces N- and C-terminal fragments that are neurotoxic in nature [40,61–63]. Tolar et al. showed 
that not only is a 22 kDa N-terminal fragment of apoE4 neurotoxic, but that it is significantly more 
toxic than the same fragment derived from the E3 isoform [62]. It has been postulated that the source 
of these toxic fragments occurs following intraneuronal processing of apoE4 [40]. Not only have these 
fragments been shown to be neurotoxic, but also may actually promote the underlying pathology 
associated with AD. Thus, N-terminal fragments of apoE4 can facilitate the production of tangle-like 
inclusions, reminiscent of early NFTs both in vitro and in animal models [34,61,63]. Similarly to the 
neurotoxic actions, it is neuron-specific proteolytic cleavage of apoE4 that is associated with increased 
phosphorylation of tau and the formation of tangle-like inclusions [38]. In addition to promoting the 
formation of tau filaments, apoE4 fragments have been shown to promote intracellular accumulation of 
the beta-amyloid peptide (1–42) [64]. In this regard, the authors found that a specific fragment of 
apoE4 promotes the cellular uptake of extracellular beta-amyloid, in vitro, and this led to the formation 
of reactive oxygen species (ROS) [64]. It is noteworthy that these in vitro findings support  
post-mortem observations in human AD brain tissue indicating an accumulation of intraneuronal  
beta-amyloid, which was correlated highly with the APOE4 genotype [65]. 
Besides the propensity of apoE4 fragments to promote the pathology associated with AD, there 
have been several reports of that apoE4 may lead to mitochondrial dysfunction [61,66,67]. 
Specifically, Nakamura et al. have shown that a specific N-terminal fragment of apoE4 is capable of 
binding mitochondrial proteins associated with oxidative phosphorylation [67]. This fragment bound to 
ubiquinol cytochrome c reductase core protein 2, cytochrome C1, and cytochrome c oxidase subunit 4 
isoform 1 leading to altered enzymatic activities as well as overall mitochondrial dysfunction [67]. 
These findings on mitochondria function have been supported by a recent study using postmortem 
brain tissue, whereby reduced mitochondrial activity was observed in young adult carriers of the 
APOE4 allele [68]. 
Functionally, apoE4 fragments have been shown to cause learning and memory deficits in 
transgenic mice. For example, apoE4 knock-in mice displayed an age-dependent decrease in 
GABAergic neurons, which was mediated through the GABAA receptor [63]. The loss of these 
neurons resulted in learning and memory deficits in these mice that were rescued following treatment 
of mice with the GABAA receptor antagonist, picrotoxin [63]. Harris et al. demonstrated that 
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expression of a C-terminal-truncated apoE4 fragment in mice resulted in behavioral deficits as well as 
neurodegeneration [34]. Finally, Bien-Ly et al. showed that expression of a C-terminal-truncated 
fragment of apoE4 not only resulted in behavior deficits in transgenic AD mice, but that this fragment 
acts in concert with beta-amyloid to elicit this effect [39]. In addition, expression of this fragment in 
AD mice led to a failure to properly clear beta-amyloid resulting in an increased beta-amyloid 
deposition [39]. Taken together these results provide strong support for a toxic-gain of function for 
cleaved fragments of apoE4 both in terms of enhancing the pathological mechanisms underlying AD, 
but also leading to functional declines in learning and memory. Figure 2 summarizes the toxic-gain of 
action of apoE4 following proteolytic cleavage in the hinge region of the protein. 
4. Targeting apoE4 Therapeutically for the Treatment of Alzheimer’s and Concluding Remarks 
The APOE4 allele represents the greatest genetic risk factor for the development of late-onset AD. 
Although clearly a risk factor, how apoE4 contributes to disease pathogenesis is currently not known. 
The purpose of this review was to assess the current state of apoE4 with regards to studies that provide 
a mechanistic foundation for how expression of the APOE4 allele confers Alzheimer’s susceptibility. 
In this regard, emerging evidence strongly suggests the link between apoE4 and disease risk is 
proteolysis of apoE4 generating N- and C-terminal fragments that may lead to loss of normal function 
or a toxic-gain of function with each possibility not mutually exclusive of each other. In either case, 
therapeutics designed to either limit proteolysis or replace cleaved apoE4 that is no longer effective 
may be a suitable treatment option. Recently, it has been shown that bexarotene (Targretin) enhances 
the expression of apoE, promotes the clearance of beta-amyloid, and reverses the behavioral deficits 
associated with AD Tg2576 transgenic mice [53]. Bexarotene is already approved by the USA Food 
and Drug Administration as an anti-cancer agent and has a favorable safety profile [69]. This is an 
important consideration as drugs that are already approved have a much clearer track to be tested in 
clinical trials. What is the putative mechanism by which bexarotene mediates the clearance of  
beta-amyloid? The authors propose that bexarotene induces the expression of the apoE through an 
action on retinoid X receptors, which act as transcription factors. The enhanced expression of apoE in 
turn, facilitates and enhances normal beta-amyloid clearance mechanisms [53]. 
Several questions remain, however, on this proposed action of bexarotene. First, what remains 
unclear is whether bexarotene increases the expression of all isoforms of apoE because treatment of 
individuals who express at least one apoE4 allele may not respond favorably, especially if a toxic-gain 
of function is the mechanism underlying the enhanced risk of AD. Second, the study by Cramer et al. 
has recently been challenged by several groups who have been unable to recapitulate central aspects of 
the study [54,56,70]. These conflicting reports suggest more studies are warranted with regards to 
bexarotene and its potential efficacy as treatment option for AD patients. 
An alternative treatment approach first suggested by the group at the Gladstone Institute of 
Neurological Disease (San Francisco, CA, USA) is the development of small-molecule structure 
correctors that could be employed to prevent the cleavage of apoE4. The basis for this approach is that 
it has been suggested apoE4’s detrimental effects result from altered protein conformation, making it 
more likely to be cleaved and producing neurotoxic fragments [71]. Recently, this group has identified 
several such compounds that reverse the neurotoxic actions of apoE4, in vitro [72,73]. The efficacy of 
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these compounds appears to be directly correlated with their ability to bind apoE4 and essentially keep 
it in an “apoE3” form that is unable to be proteolyzed [71]. The Gladstone group has also published 
tantalizing in vivo data showing these apoE4 structure correctors are not toxic and result in a  
20%–25% decrease in the levels of apoE4 fragments in the brain of apoE4-expressing mice [71]. Their 
data suggest that structure-corrector-based therapies targeted towards apoE4 carriers could provide a 
therapeutic avenue for the treatment of AD. Perhaps the time has come to flesh out these potential 
treatment opportunities considering that 65%–80% of all AD patients have at least one apoE4  
allele [28] and apoE4 expression decreases the age of onset, resulting in cognitive deficits 7–8 years 
earlier in individuals carrying one allele and 15–16 years earlier in those carrying two alleles [74].  
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